Association between leptin receptor polymorphisms and polycystic ovary syndrome risk: a meta-analysis based on 11 studies

Figures & data

Table 1. Characteristics of case–control studies on LEPR polymorphisms and PCOS risk in the meta-analysis.

First author	Year	Country/Ethnicity	Control design	Genotyping method	Case	Control	Genotype distribution						P for HWE	NOS Assessment
							Case			Control
rs1137101							AA	AG	GG	AA	AG	GG
Oksanen [6]	2000	Finland/Caucasian	HB	PCR-RFLP	38	122	46^a	30^b		146^a	98^b		NA	6
Erel [7]	2002	Turkey/Caucasian	HB	PCR-RFLP	56	58	19	24	13	21	30	7	0.453	7
Chen [8]	2011	China/Asian	HB	PCR-RELP	56	32	1	11	44	1	5	26	0.263	8
Li [4]	2013	Korea/Asian	HB	PCR-RELP	229	150	89	128	12	27	88	35	0.030	8
Yang [9]	2015	China/Asian	PB	PCR-sequencing	100	154	0	13	87	1	33	120	0.429	7
Smaism [10]	2016	Iraq/Caucasian	NA	PCR-RELP	30	20	12	15	3	11	13	6	0.552	6
Tu [11]	2017	China/Asian	PB	PCR-sequencing	326	280	3	66	257	3	56	221	0.793	8
Daghestani [12]	2019	Saudi/Caucasian	PB	PCR-sequencing	130	122	85	29	16	82	23	17	<0.001	6
Dallel-1 [13]	2021	Tunisia/Caucasian	HB	TaqMan	320	446	112	150	58	165	196	85	0.052	11
Dallel-2 [13]	2021	Bahrain/Caucasian	HB	TaqMan	242	238	99	99	44	140	74	24	0.004	10
Naseri [14]	2021	Iran/Caucasian	HB	PCR-RFLP	100	100	37	53	10	17	59	24	0.063	8
Kargasheh [15]	2021	Iran/Caucasian	HB	PCR-RFLP	263	83	126	115	22	32	37	14	0.558	9
rs1137100							AA	AG	GG	AA	AG	GG
Oksanen [6]	2000	Finland/Caucasian	HB	PCR-RFLP	38	122	54^a	22^b		158^a	86^b		NA	6
Tu [11]	2017	China/Asian	PB	PCR-sequencing	326	283	6	95	225	16	80	187	0.065	8
Dallel-1 [13]	2021	Tunisia/Caucasian	HB	TaqMan	320	446	247	70	3	339	94	13	0.045	10
Dallel-2[13]	2021	Bahrain/Caucasian	HB	TaqMan	242	238	177	60	5	157	63	18	0.002	10
rs1805096							CC	CT	TT	CC	CT	TT
Li [4]	2013	Korea/Asian	HB	PCR-RELP	229	150	137	87	5	108	41	1	0.166	9
Naseri [14]	2021	Iran/Caucasian	HB	PCR-RFLP	100	100	59	34	7	80	19	1	0.913	8

a: A allele; b: G allele.

HWE in control.

NA: Not available.

PCR-APLP: Polymerase chain reaction-amplified product length polymorphism.

PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism.

HB: Healthy controls; PB: Patients controls with other illness.

Figure 1. Flow diagram of the study selection process.

Figure 2. OR and 95% CIs of the associations between LEPR rs1137101 a/G polymorphism and PCOS susceptibility in G versus A model.

Table 2. Summary ORs and 95% CI of LEPR polymorphisms and PCOS risk.

		OR	95% CI	P	I^2(%)	OR	95% CI	P	I^2(%)	OR	95% CI	P	I^2(%)	OR	95% CI	P	I^2(%)	OR	95% CI	P	I^2(%)
rs1137101 A/G	N*	G vs. A				AG vs. AA				GG vs. AA				AG + GG vs. AA				GG vs. AA + AG
Total	12	0.93	0.70–1.23	0.61	83.3	0.92	0.64–1.31	0.64	64.8	0.70	0.36–1.40	0.32	83.4	0.87	0.57–1.32	0.50	78.1	0.81	0.539–1.25	0.34	78.4
HWE Status
Yes	8	0.91	0.70–1.18	0.47	63.7	1.09	0.83–1.43	0.53	8.6	0.70	0.37–1.32	0.27	59.4	0.87	0.70–1.08	0.21	38.7	0.87	0.59–1.28	0.48	60.0
No	4	0.94	0.47–1.91	0.87	93.5	1.01	0.41–2.52	0.98	89.8	0.63	0.10–4.04	0.63	95.3	0.93	0.32–2.69	0.89	93.9	0.69	0.17–2.84	0.60	93.0
Ethnicity
Caucasian	8	0.95	0.70–1.29	0.76	80.6	1.01	0.70–1.45	0.95	64.6	0.82	0.43–1.57	0.55	80.7	0.96	0.63–1.45	0.83	77.6	0.86	0.52–1.42	0.56	71.6
Asian	4	0.90	0.47–1.72	0.75	85.8	0.51	0.32–0.81	0.01	0	0.60	0.10–3.69	0.59	74.2	0.41	0.26–0.65	<0.01	25.9	0.73	0.28–1.91	0.53	87.8
Language
English	10	0.88	0.65–1.19	0.41	85.4	0.90	0.62–1.31	0.59	71.5	0.65	0.31–1.34	0.24	86.6	0.84	0.54–1.31	0.44	82.4	0.73	0.45–1.18	0.20	80.7
Chinese	2	1.50	0.88–2.57	0.14	21.6	1.65	0.18–15.43	0.66	0	1.91	0.23–15.67	0.14	0	1.86	0.23–15.39	0.56	0	1.51	0.85–2.68	0.16	32.8
Control design
HB	8	0.87	0.59–1.27	0.46	88.5	0.85	0.53–1.36	0.49	78.5	0.64	0.25–1.61	0.34	89.9	0.80	0.46–1.40	0.44	86.7	0.71	0.37–1.37	0.31	84.9
PB	3	1.12	0.83–1.52	0.47	27.8	1.21	0.68–1.25	0.51	0	0.46	0.09–2.29	0.97	0	1.11	0.68–1.81	0.68	0	1.11	0.82–1.51	0.47	33.7
Genotyping methods
PCR- RFLP	7	0.71	0.52–0.97	0.03	65.7	0.60	0.45–0.80	<0.01	18.8	0.40	0.16–1.03	0.06	76.9	0.53	0.40–0.70	<0.01	52.2	0.51	0.25–1.03	0.06	71.9
PCR-sequencing	3	1.10	0.86–1.42	0.44	27.8	1.21	0.68–1.25	0.51	0	0.99	0.51–1.91	0.97	0	1.11	0.68–1.81	0.68	0	1.11	0.82–1.51	0.50	37.3
TaqMan	2	1.36	0.77–2.40	0.29	90.9	1.44	0.87–2.39	0.16	74.8	1.58	0.63–4.00	0.33	86.0	1.41	1.12–1.78	<0.01	85.8	1.33	0.64–2.76	0.44	80.3
rs1137100 A/G		G vs. A				AG vs. AA				GG vs. AA				AG + GG vs. AA				GG vs. AA + AG
Total	4	0.87	0.64–1.19	0.38	67.6	1.16	0.70–1.92	0.57	66.1	0.64	0.12–3.56	0.61	86.9	1.08	0.61–1.92	0.79	0.757	0.50	0.16–1.55	0.23	81.0
rs1805096 C/T		T vs. C				CT vs. CC				TT vs. CC				CT + TT vs. CC				TT vs. CC + CT
Total	2	2.00	1.21–3.30	0.01	54.7	1.88	1.30–2.73	<0.01	0	6.29	1.40–28.33	0.02	0	2.02	1.41–2.90	<0.01	31.6	5.14	1.15–23.06	0.03	0

*Numbers of comparisons.

Oksanen L, Tiitinen A, Kaprio J, et al. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod. 2000;6(10):873–876. doi: 10.1093/molehr/6.10.873.

 PubMed Web of Science ®Google Scholar

Erel CT, Cine N, Elter K, et al. Leptin receptor variant in women with polycystic ovary syndrome. Fertil Steril. 2002;78(6):1334–1335. doi: 10.1016/s0015-0282(02)04352-2.

 PubMed Web of Science ®Google Scholar

Chen Y. The relationship between polymorphism of the Gln223Arg gene of leptin receptor and insulin resistance and lipid metabolism in polycystic ovary syndrome. Proc Clin Med. 2011;20:912–914.

 Google Scholar

Li L, Lee KJ, Choi BC, et al. Relationship between leptin receptor and polycystic ovary syndrome. Gene. 2013;527(1):71–74. doi: 10.1016/j.gene.2013.05.074.

 PubMed Web of Science ®Google Scholar

Yang MY, Song QQ, Zhao XK, et al. Association between polymorphism of leptin receptor gene Gln223Arg and polycystic ovary syndrome. Clin J Med Offic. 2015;43:855–858.

 Google Scholar

Smaism MF. Assessment of leptin levels in the different genotypes and leptin receptor genes in the women with polycystic ovary syndrome and diabetes mellitus type 2 in Iraq population. Int J PharmTech Res. 2016;9:269–276.

 Google Scholar

Tu X, Yu C, Gao M, et al. LEPR gene polymorphism and plasma soluble leptin receptor levels are associated with polycystic ovary syndrome in Han Chinese women. Per Med. 2017;14(4):299–307. doi: 10.2217/pme-2017-0016.

 PubMed Web of Science ®Google Scholar

Daghestani MH, Daghestani MH, Daghistani MH, et al. The influence of the rs1137101 genotypes of leptin receptor gene on the demographic and metabolic profile of normal Saudi females and those suffering from polycystic ovarian syndrome. BMC Women’s Health. 2019;19:10.

 Google Scholar

Dallel M, Douma Z, Finan RR, et al. Contrasting association of leptin receptor polymorphisms and haplotypes with polycystic ovary syndrome in Bahraini and Tunisian women: a case-control study. Biosci Rep. 2021;41(1):41.

 Web of Science ®Google Scholar

Naseri R, Barzingarosi E, Sohrabi M, et al. The effect of leptin receptor gene polymorphisms (R223Q and P1019P) in susceptibility to polycystic ovarian syndrome in kurdish women. Int J Fertil Steril. 2021;15:123–127.

 PubMed Web of Science ®Google Scholar

Kargasheh FB, Ansaripour S, Borumandnia N, et al. Association of leptin G2548A and leptin receptor Q223R polymorphisms and their serum levels with infertility and recurrent pregnancy loss in iranian women with polycystic ovary syndrome. PLoS One. 2021;16(8):e0255920. doi: 10.1371/journal.pone.0255920.

 PubMed Web of Science ®Google Scholar

Data availability statement

The datasets used or analyzed in this study are available from the corresponding author on reasonable request.